Loading...
•
Jun 30, 2024
ResMed Q4 2024 Earnings Report
ResMed's Q4 2024 earnings were announced, demonstrating revenue growth, improved gross margin, and increased profitability.
Key Takeaways
ResMed Inc. reported a 9% increase in revenue to $1.2 billion for the fourth quarter of fiscal year 2024. The company's operating profit increased by 38%, with non-GAAP operating profit up by 30%. Diluted earnings per share were reported at $1.98, and non-GAAP diluted earnings per share at $2.08.
Revenue increased by 9% year-over-year, reaching $1.2 billion.
Operating profit surged by 38%, while non-GAAP operating profit rose by 30%.
Gross margin improved by 350 bps to 58.5%, with non-GAAP gross margin improving by 330 bps to 59.1%.
Diluted earnings per share (EPS) reached $1.98, and non-GAAP diluted EPS was $2.08.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
ResMed did not provide a detailed forward guidance in the earnings report. However, the CEO mentioned the company is well-positioned to drive increased market penetration and accelerate growth.
Positive Outlook
- Ongoing patient and customer demand for best-in-class products and software solutions.
- Focus on operating excellence and cost discipline.
- Profitable growth acceleration.
- Increasing awareness with the fast-growth population of sleep-health-interested consumers.
- Creating virtual pathways that expand access to therapies.
Challenges Ahead
- No specific negative aspects were mentioned in the earnings report.
- The report focuses on the positive aspects and future opportunities.
- The company is operating in significantly underpenetrated markets, which presents both an opportunity and a challenge.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...